ArticleJournal of hepatology2016
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Article in Journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver DiseaseFrontiers in nutrition · 2022Pooled it
- A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).Scientific reports · 2021Pooled it
- Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?Biomedicines · 2025Article
- Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC).Nutrition & metabolism · 2024Review
- Hepatic glucose metabolism in the steatotic liver.Nature reviews. Gastroenterology & hepatology · 2024Review
- Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.Journal of clinical medicine · 2023Review
- Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.Clinical and molecular hepatology · 2022Review
- Therapeutic Potential of Quercetin in the Management of Type-2 Diabetes Mellitus.Life (Basel, Switzerland) · 2022Review
- Nonalcoholic Fatty Liver Disease.Handbook of experimental pharmacology · 2022Review
- Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.Acta pharmaceutica Sinica. B · 2020Review
- Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives.International journal of environmental research and public health · 2019Review
- From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.JHEP reports : innovation in hepatology · 2019Review
- Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.International journal of molecular sciences · 2019Review
- Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?Pharmaceuticals (Basel, Switzerland) · 2018Review
- [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Review
- Pathophysiology of Non Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2016Review
- The role of the gut microbiota in NAFLD.Nature reviews. Gastroenterology & hepatology · 2016Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26643784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.